Scott Andrew Smith
CIK 1614975 · Chief Executive Officer · last filed 2026-03-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BCAB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
86 MORRIS AVENUE
SUMMIT, NJ 07901
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VTRS | Chief Executive Officer | 1,331,759 | $20.46 | $27.25M | $756.0K | 8 | 2026-03-10 |
| BioAtla, Inc. (BCAB) Delisted | Director | 6,431 | $1.74 | $11.2K | -$1.57M | 44 | 2025-06-18 |
| Apexigen, Inc. (APGNW) Delisted | Director | — | $0.03 | — | $0 | 1 | 2022-10-03 |
| F-star Therapeutics, Inc. (SBPH) Delisted | Director | 9,369 | — | — | $49.1K | 8 | 2020-06-25 |
| CELGENE CORP /DE/ (CELGZ) Delisted | See Remarks | 54,536 | — | — | $0 | 23 | 2018-02-20 |
| TITAN PHARMACEUTICALS INC (TTNP) Delisted | Director | — | $4.61 | — | $0 | 1 | 2017-09-19 |
Recent Filings · Page 6 of 9
86 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-10-07 | BioAtla, Inc. (BCAB) Delisted | Sell (S) | −2,994 | -$90.4K | EDGAR |
| 2021-08-30 | BioAtla, Inc. (BCAB) Delisted | Sell (S) | −33,244 | -$1.33M | EDGAR |
| 2021-06-16 | BioAtla, Inc. (BCAB) Delisted | Other (J) | +34,963 | $0 | EDGAR |
| 2020-12-17 | BioAtla, Inc. (BCAB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-25 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-01-02 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | +12,500 | $0 | EDGAR |
| 2019-10-01 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | +5,741 | $0 | EDGAR |
| 2019-07-11 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-07-01 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | +5,352 | $0 | EDGAR |
| 2019-06-28 | F-star Therapeutics, Inc. (SBPH) Delisted | Buy (P) | +12,000 | $49.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.